• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • COVID-19 Patient Resource Center
    • Clinical Trials
    • Search Clinical Trials
    • Patient Notification System
    • What is Clinical Research?
    • Volunteering for a Clinical Trial
    • Understanding Informed Consent
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Clinical Trial Listings
    • Market Research
    • FDA Approved Drugs
    • Training Guides
    • Books
    • eLearning
    • Events
    • Newsletters
    • White Papers
    • SOPs
    • eCFR and Guidances
  • White Papers
  • Trial Listings
  • Advertise
  • COVID-19
  • iConnect
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » Daiichi forms diabetes alliance with NGM Biopharma

Daiichi forms diabetes alliance with NGM Biopharma

March 30, 2012
CenterWatch Staff

Tokyo-based Daiichi Sankyo has formed a partnership with San Francisco-based NGM Biopharmaceuticals to research and develop new treatments for diabetes.

Daiichi will make use of NGM’s discovery technology and in vivo screening platform to identify drug targets that influence the growth and functionality of beta cells, which store and release insulin. NGM’s research platform aims to discover therapies that can cause these beta cells to regenerate.

Research will be funded by Daiichi, but scientists from both companies will work together to develop drug candidates. NGM will receive an undisclosed upfront payment as part of the deal, as well as milestone payments if certain development and commercial goals are reached and royalties on product sales if a product makes it to market. In return, Daiichi will receive an exclusive worldwide license to develop and commercialize any products developed as part of the collaboration.

“We are extremely confident that this collaboration will expand our research activities in the cardiovascular metabolic area, which is a high priority target area for our company,” said Dr Kazunori Hirokawa, global head of Daiichi Sankyo's R&D unit. “Furthermore, I expect this collaboration to result in an innovative pharmaceutical product that meets an unmet medical need in the cardiovascular metabolic area.”

Other pharma companies looking at ways to stimulate growth of beta cells include Roche, which is working with JDRF and has published research claiming to have found a protein that regulates beta cell growth and a compound that stimulates it. Eli Lilly is also working with the JDRF to investigate compounds that can regenerate beta cells and Boehringer Ingelheim recently partnered with a German university to research the causes of diabetes, including the genetic reasons behind the destruction of beta cells in people with type 1 diabetes.

Upcoming Events

  • 16Feb

    Fundamentals of FDA Inspection Management: Reduce Anxiety, Increase Inspection Success

  • 21May

    WCG MAGI Clinical Research Conference – 2023 East

Featured Products

  • Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

    Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

  • Surviving an FDA GCP Inspection

    Surviving an FDA GCP Inspection: Resources for Investigators, Sponsors, CROs and IRBs

Featured Stories

  • Revamp-360x240.png

    Califf Calls for Major Evidence Generation Revamp, Experts’ Opinions Differ

  • AskTheExpertsGreen-360x240.png

    Ask the Experts: Managing Investigational Products

  • SurveywBlueBackground-360x240.png

    Survey Outlines Site Challenges, Successes on Diversity

  • PatientCentricity-360x240.png

    Site Spotlight: DM Clinical Shows Patient Centricity Doesn’t Have to Break the Bank

Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

The information you need to adapt your monitoring plan to changing times.

Learn More Here
  • About Us
  • Contact Us
  • Privacy Policy
  • Do Not Sell or Share My Data

Footer Logo

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

Phone 617.948.5100 – Toll free 866.219.3440

Copyright © 2023. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing